Surgical Management of Right Colon Cancer with Hepatic Metastases

Introduction to Treatment Approach

The American Society of Clinical Oncology recommends initiating treatment with neoadjuvant chemotherapy followed by sequential surgery, starting with hepatic resection (liver-first approach) and then resection of the primary tumor, for patients with resectable right colon cancer and hepatic metastases 1
The European Society for Medical Oncology suggests that hypalbuminemia (2.6 g/dL) indicates a deficient nutritional state that increases surgical risk, and should be optimized before any surgical intervention 2

The National Comprehensive Cancer Network recommends that hepatic metastases confined to the right lobe are technically resectable if an adequate liver remnant (>30% of liver volume) can be maintained 3, 4
The British Journal of Cancer states that the liver-first approach is justified because hepatic metastases determine the patient's vital prognosis, and the goal is to achieve R0 resection of all metastases 2, 5

The National Comprehensive Cancer Network suggests initiating systemic neoadjuvant chemotherapy for 2-3 months to evaluate tumor biology and treat micrometastatic disease, with recommended regimens including FOLFOX or FOLFIRI, depending on the patient's condition 3, 6
The American Society of Clinical Oncology recommends completing a total of 6 months of perioperative chemotherapy, with the same regimen that showed efficacy in the neoadjuvant phase 3, 6

The British Journal of Cancer describes the technique for hepatic resection as a right hepatectomy with adequate oncologic margins (1 cm), aiming for R0 resection of all metastases 2, 5
The National Comprehensive Cancer Network recommends a right hemicolectomy with adequate lymphadenectomy for resection of the primary tumor, aiming for R0 resection with adequate margins 2, 7

The British Journal of Cancer suggests that low albumin levels (2.6 g/dL) require preoperative nutritional optimization through enteral or parenteral nutritional supplementation, and monitoring of nutritional parameters during neoadjuvant chemotherapy 2

The American Society of Clinical Oncology recommends that the final decision be made in a multidisciplinary committee that includes colorectal, hepatobiliary, and medical oncologists, as well as radiologists 1

Symptomatic primary lesions, such as hemorrhage or obstruction, should have primary disease addressed first, according to the International Journal of Surgery guidelines 8

Combined resection of primary tumor and liver metastases can be considered for accessible small metastases, and should be performed only in high-volume centers with appropriate experience in liver resectional surgery, as recommended by Gut 9
Synchronous primary resection with complex liver procedures like ALPPS is not advisable due to increased morbidity and mortality, as stated in the International Journal of Surgery 8

Neoadjuvant chemotherapy can downsize initially unresectable liver metastases, making them amenable to curative resection, as reported in Gut 10, 11
Response to chemotherapy may serve as a surrogate marker for subsequent liver resection rates with curative intent, according to Gut 10, 11

All treatment decisions should be made by a multidisciplinary team including colorectal surgeons, hepatobiliary surgeons, medical oncologists, and radiologists, as recommended by Gut 12
Follow-up should continue for five years according to local protocol using CT chest, liver imaging, and CEA monitoring, as stated in Gut 13, 12
Re-resection can be considered for recurrent liver metastases with similar outcomes to initial hepatectomy, as reported in Gut 9, 12